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The amino-acid mutational spectrum of human genetic diseas Nonsynonymous mutations in the coding regions of human genes are responsible for phenotypic differences between humans and for sus- ceptibility to genetic disease. Computational methods were recently used to predict deleterious effects of nonsynonymous human mutations  and polymorphisms. Here we focus on understanding the amino-acid mutation spectrum of human genetic disease. We compare the dis- ease spectrum to the spectra of mutual amino-acid mutation frequencies, non-disease polymorphisms in human genes, and substitutions  fixed between species.
Abstract
Background: Nonsynonymous mutations in the coding regions of human genes are responsible
for phenotypic differences between humans and for susceptibility to genetic disease.
Computational methods were recently used to predict deleterious effects of nonsynonymous
human mutations and polymorphisms. Here we focus on understanding the amino-acid mutation
spectrum of human genetic disease. We compare the disease spectrum to the spectra of mutual
amino-acid mutation frequencies, non-disease polymorphisms in human genes, and substitutions
fixed between species.
Results:  We find that the disease spectrum correlates well with the amino-acid mutation
frequencies based on the genetic code. Normalized by the mutation frequencies, the spectrum can
be rationalized in terms of chemical similarities between amino acids. The disease spectrum is
almost identical for membrane and non-membrane proteins. Mutations at arginine and glycine
residues are together responsible for about 30% of genetic diseases, whereas random mutations at
tryptophan and cysteine have the highest probability of causing disease.
Conclusions: The overall disease spectrum mainly reflects the mutability of the genetic code. We
corroborate earlier results that the probability of a nonsynonymous mutation causing a genetic
disease increases monotonically with an increase in the degree of evolutionary conservation of the
mutation site and a decrease in the solvent-accessibility of the site; opposite trends are observed
for non-disease polymorphisms. We estimate that the rate of nonsynonymous mutations with a
negative impact on human health is less than one per diploid genome per generation.
Background
Several recent studies [1-6] have applied computational
methods to predict potentially deleterious effects of nonsyn-
onymous single-nucleotide polymorphisms (SNPs) in
humans. SNPs represent common human alleles, usually
with population frequencies greater than 1%. Both structural
and evolutionary methods were used to assess potential func-
tional effects of SNPs. It was predicted that a substantial
fraction (10-30%) of human SNPs may affect protein function
negatively, although the medical consequences of these SNPs
remain to be established.
The main goal of the work reported here is to characterize and
rationalize the overall amino-acid spectrum of disease muta-
tions and non-disease SNPs (referred to as 'benign SNPs'
below). We obtain the relative probabilities that a random
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mutation (rather than an existing SNP) will cause a genetic
disease while explicitly taking into account the underlying
spectrum of nucleotide mutations. Such an approach will
allow, in the future, the identification and characterization of
highly mutable sites in the human genome which are also
functionally important.
Miller and Kumar [5] performed a detailed analysis of the dis-
ease mutations and benign SNP spectra in seven human
genes. While some of our results are consistent with their
study, we find major differences. For example, we observe a
significantly larger contribution of mutations at arginine
(Arg) and glycine (Gly) to human genetic disease. We
attribute the differences to the substantially larger gene set
(436 genes versus 7) used in our analysis.
Results and discussion
Overall amino-acid mutational spectrum
We present the amino-acid spectra of disease mutations and
polymorphisms in Figure 1. The mutations from the Mende-
lian Inheritance in Man (MIM) database [7] annotated in
SWISS-PROT [8] were used as a source of human disease
mutations. In total, 4,236 mutations from 436 genes were
considered. The collection of 1,037 synonymous and nonsyn-
onymous SNPs from the extensive analysis of haplotypes in
313 human genes [9] was used as a source of benign SNPs.
There was no overlap between the disease mutations and
benign sets of SNPs used in the study. The spectrum of inter-
species substitutions (Figure 1d) was calculated on the basis
of the PAM1 matrix [10] as described in Materials and
methods.
Nearly all mutations in the current MIM database represent
Mendelian disease (monogenic in etiology). It remains to be
seen to what extent our results pertain to disease mutation
involved in polygenic disorders. At this point, too little is
known about this type of mutation, and more experimental
work is required in order to understand their spectrum.
The mutation matrices in Figure 1 are sparse (that is, a large
number of the matrix elements are close or equal to zero) and
nonsymmetrical (in many cases the tendency of amino acid I
to mutate into amino acid J is different from the tendency of
amino acid J to mutate into I). The vast majority of human
genetic mutations are caused by single-nucleotide changes
[11,12]. Consequently, the matrices in Figure 1b,c,d repre-
sent amino-acid transitions resulting predominantly from
single-nucleotide mutations in amino-acid codons. To ration-
alize the observed disease and benign spectra, we generated
the expected mutation spectrum (Figure 1a) using the neigh-
bor-dependent matrix of nucleotide mutation rates devel-
oped by Hess et al. [13] (see Materials and methods). The
expected mutation matrix in Figure 1a represents the spec-
trum which would be observed if all nonsynonymous muta-
tions were accepted (that is, there were no selection). The
expected spectrum was generated for the disease genes con-
sidered and, separately, for a large collection of more than
7,000 human genes available from SWISS-PROT. These two
spectra were almost identical (R = 0.98, p < 0.0001), suggest-
ing that the expected spectrum in Figure 1a reflects general
properties of all human genes (such as amino-acid codon fre-
quencies and context-dependent nucleotide mutation fre-
quencies). Here and throughout the paper we use the t-test
statistics with n-2 degrees of freedom to estimate the signifi-
cance of linear correlations. Random shuffling simulations
confirmed the significance values obtained using the t-test.
The spectrum of disease mutations was calculated separately
for membrane proteins. The program TMHMM [14] was used
to detect potential transmembrane regions. The disease spec-
trum for membrane proteins is very similar to the all-protein
disease spectrum (R = 0.97, p < 0.0001 for all disease muta-
tions in membrane proteins, 1,598 in total; R = 0.75, p <
0.0001 for disease mutations in transmembrane regions, 372
in total). Evidently, specific properties of membrane proteins
and the constraints on them are not able to significantly mod-
ify the disease spectrum common to all proteins.
Correlations between the expected and the observed 
spectra
Close-to-diagonal mutations in Figure 1a,b,c,d represent
substitutions between amino acids with similar chemical
properties (conservative mutations). The interspecies substi-
tutions (Figure 1d) contain the highest fraction of conserva-
tive mutations compared to disease mutations and benign
SNPs. The frequencies of the benign SNPs, disease mutations,
and interspecies substitutions are plotted versus expected
frequencies in Figure 2. Benner et al. [15] showed that the
genetic code affects the amino-acid substitution spectrum at
early stages of divergence, whereas chemical similarities
dominate at longer evolutionary distances. The correlation
between the benign and expected spectra observed in our
study (R = 0.78, p < 0.0001), is an expected extension of Ben-
ner's et al. conclusion to even shorter evolutionary distances
(variations within a population).
Interestingly, we also find a strong correlation of the disease
mutation spectrum with the expected spectrum based on the
genetic code (R = 0.71, p < 0.0001). The correlation of disease
mutation frequencies with the chemical dissimilarities
between original and mutant amino acids is apparent only
after normalization by the expected frequencies (Figure
3a,b). Consequently, in the majority of cases the comparison
of amino-acid types (wild type versus mutant) will be insuffi-
cient to distinguish neutral from disease variants.
The contribution of mutations at different amino acids to the
disease spectrum is highly heterogeneous (Figure 4). Inter-
estingly, mutations at Arg residues account for almost 15% of
the disease mutations. This is a direct consequence of the
well-known high mutability of Arg (due to deamination ofhttp://genomebiology.com/2003/4/11/R72 Genome Biology 2003,     Volume 4, Issue 11, Article R72       Vitkup et al. R72.3
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Genome Biology 2003, 4:R72
5'-CpG dinucleotides in Arg codons) [16,17], the relatively
high frequency of Arg in human proteins (<4%), and the fact
that Arg mutates to residues with very different chemical
properties (cysteine (Cys), glycine (Gly), histidine (His),
lysine (Lys), leucine (Leu), methionine (Met), proline (Pro),
flutamine (Gln), serine (Ser) and tryptophan (Trp)). The rel-
ative probability of a disease mutation at different amino
acids (Figure 4b) was calculated by dividing the disease and
expected frequencies. Accordingly, a random mutation at a
Trp or Cys residue has the highest probability of causing a dis-
ease. This correlates well with the highest evolutionary con-
servation of exactly these two residues [10]. Both Trp and Cys
residues play a prominent part in determining protein stabil-
ity. In addition to Trp and Cys, the high probability of disease
mutations at Gly may be related to important structural roles
often played by this residue. For example, mutations at Gly,
Amino-acid mutation frequencies in human genes Figure 1
Amino-acid mutation frequencies in human genes. (a) The expected mutation frequencies based on the neighbor-dependent nucleotide mutation rates. 
The expected mutation matrix represents the frequencies of amino-acid transitions in the absence of selection. (b) The nonsynonymous benign SNP 
frequencies using the SNP dataset of Stephens et al. [9]. (c) The genetic disease mutation frequencies based on the Mendelian Inheritance in Man (MIM) 
database [7]. (d) The interspecies mutation frequencies based on the PAM1 matrix [10]. In the matrices, each square represents a particular amino-acid to 
amino-acid mutation (for example, Val → Ala). The gray level of the matrix squares is proportional to the number of observed mutations. The matrices 
were normalized so that the sum over all mutation frequencies for each matrix is equal to 100. The y-axes of the matrices represent the original (wild-
type) amino acids; the x-axes represent the mutant amino acids (created as a result of a single-nucleotide mutation). The amino acids (given in single-letter 
amino-acid code) were ordered along the axes according to the side-chain chemistry [42]: (C) sulfhydryl; (STPAG) small hydrophilic; (NDEQ) acid, acid 
amide and hydrophilic; (HRK) basic; (MILV) hydrophobic; (FYW) large hydrophobic/aromatic. As a result of the ordering, the mutations close to the 
matrix diagonal tend to be more conserved.
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which is frequently present at the turns of alpha-helices,
might have a negative impact on protein structural stability.
Our definition of the relative probability of disease mutations
is similar to the relative clinical observation likelihood
(RCOL) used by Cooper et al. in several publications (see, for
example [6]). In the next section we extend the relative prob-
abilities to interspecies comparisons.
Probabilities of mutations or SNPs as a function of the 
mutation/SNP-site properties
To complement the analysis of the amino-acid mutation
matrices, we investigated how the probabilities of benign
SNPs and disease mutations depend on the properties of the
mutation site. Several recent studies have focused on devel-
oping evolutionary and structural approaches to predict
potentially deleterious human mutations [1-4,18,19]. Here,
we focus on understanding the relative mutation probabilities
(see Materials and methods). Our results are in general agree-
ment with the previous studies. The relative probabilities of
disease mutations and benign SNPs are shown in Figure 5a as
a function of the interspecies evolutionary conservation of the
mutation site. The conservation was characterized by the rel-
ative entropy measure using homologs with more than 30%
sequence identity. The probability that a random mutation
will cause a genetic disease increases monotonically with an
increase in the degree of site conservation, while the
The expected frequencies of amino-acid to amino-acid mutations versus observed frequencies of the genetic disease mutations, nonsynonymous benign  SNPs, and interspecies mutations Figure 2
The expected frequencies of amino-acid to amino-acid mutations versus observed frequencies of the genetic disease mutations, nonsynonymous benign 
SNPs, and interspecies mutations. Comparison with (a) genetic disease mutations from the Mendelian Inheritance in Man (MIM) database [7], (b) 
nonsynonymous benign SNPs, based on the study by Stephens et al. [9], and (c) interspecies mutations based on the PAM1 matrix [10]. Each point in the 
figure represents a certain type of amino-acid to amino-acid mutation. Only amino-acid transitions resulting from single-nucleotide mutations in amino-acid 
codons were considered. The mutation frequencies in each class (benign, disease and interspecies) were normalized to 100.
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probability of observing nonsynonymous benign SNPs shows
the opposite trend. The synonymous benign SNPs do not
change amino acids and should be predominantly neutral. As
a result, their probability is uniform across sites.
The solvent accessibility of an amino-acid residue in a protein
reflects the degree of the residue's exposure to the surround-
ing solvent in the protein structure. The relative probability of
disease-causing mutations is highest in the protein interior
and lowest on the protein surface (Figure 5b). The benign
SNPs show the reverse trend, as their relative probability is
highest on the surface and lowest in the protein interior. This
is consistent with the study by Moult and co-workers [1] (see
also Ferrer-Costa et al. [20] and Bustamente et al. [21]), who
suggested that the dominant mechanism by which disease
mutations damage protein function is a decrease in protein
stability, as opposed to mutations of active-site residues (usu-
ally located on the protein surface).
Both relative entropy and solvent accessibility exclusively
characterize the site of a mutation. To estimate the extent to
which a given amino acid is incompatible with the residues
observed at the same position in close homologs, we intro-
duced the Grantham Ratio (GR) score based on the Grantham
dissimilarity matrix [22] (see Materials and methods for a
formal definition). Application of other scores, for example
those based on the BLOSUM matrices, gave qualitatively sim-
ilar results [3]. The GR score is the ratio of two averages - the
numerator being the average dissimilarity between the
mutated amino acid and the residues observed at the same
site in evolution, and the denominator being the average dis-
similarity within the residues observed at the site in homolo-
gous proteins. Defined in this way, a GR score smaller or close
to 1 suggests that the amino acid is similar to the residues
observed at the site in evolution, whereas a GR score signifi-
cantly larger than 1 indicates that the amino-acid change is
evolutionarily radical.
The role of purifying selection in shaping the mutation spec-
tra is apparent from the cumulative distribution of the GR
scores (Figure 6). Whereas the GR distribution for original
(wild type) residues at benign sites (blue curve) is very similar
to the distribution for all protein residues (black), the distri-
bution for mutant residues at benign sites (green) clearly
shows an excess of radical mutations. Importantly, the GR
distribution of mutant residues at benign sites (green) is sim-
ilar to the distribution for randomly generated mutations
(cyan) and is quite different from the disease mutation distri-
bution (red). Consequently, although a significant fraction of
randomly arising nonsynonymous mutations are evolution-
arily radical (and thus potentially deleterious) they are not, on
average, as radical as the disease mutations and still have
appreciable frequencies in the human population. Indeed, it
was recently estimated [23] that the average reduction in evo-
lutionary fitness due a mildly deleterious SNP with a signifi-
cant frequency in the human population is in the range of
0.01-1%. The medical importance of such mildly deleterious
human mutations remains to be established [24,25].
The cumulative distribution of the GR scores for disease
mutations suggests that more than a half of the disease
Chemical dissimilarities between original and mutant amino acids versus  observed mutation frequencies Figure 3
Chemical dissimilarities between original and mutant amino acids versus 
observed mutation frequencies. (a) The amino-acid dissimilarities versus 
the frequencies of disease mutations. (b) The amino-acid dissimilarities 
versus the relative frequencies of genetic disease mutations (normalized by 
site mutabilities). The chemical dissimilarities between amino acids were 
characterized using the Grantham score [22]. Each point in the figure 
represents a certain type of amino-acid to amino-acid mutation. Only 
amino-acid transitions resulting from single-nucleotide mutations in amino-
acid codons were considered. The mutation frequencies in (a) were 
normalized to 100. The relative frequencies in (b) were determined as the 
ratio between the disease and the expected mutation frequencies (see 
Figure 1). The relative frequencies are proportional to the relative 
probabilities of amino-acid mutations causing a disease. No correlation 
between the disease mutation frequencies and chemical dissimilarities is 
evident (a), but there is a significant correlation between the normalized 
frequencies and the chemical dissimilarities (b).
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mutations are evolutionarily radical (represented by residues
with GR score greater than 2). Residues with such GR scores
are almost never observed in homologous sequences (blue
and black curves). It is important to note that medically dam-
aging mutations and SNPs cannot always be rationalized in
terms of evolutionary radicality. Medically harmful
Contribution of mutations at different amino acids to the overall mutation spectrum Figure 4
Contribution of mutations at different amino acids to the overall mutation spectrum. (a) The fraction of mutations at different amino acids. The fractions 
are shown separately for benign, expected and disease mutations (normalized to 100% within each class). The contribution of mutations at different amino 
acids to the overall spectrum is highly heterogeneous. For example, mutations at arginine (R) constitute approximately 15% of all mutations. This is a direct 
consequence of a high mutability of the 5'-CpG dinucleotides in the arginine codons. (b) The relative probability that a random mutation at different amino 
acids will cause a genetic disease. Importantly, because the overall probability that a random mutation will cause a genetic disease is unknown, the 
probabilities in (b) have only relative meaning (for example, the probability that a random mutation will cause a disease mutation at alanine (A) versus 
valine (V)). For display purposes it was assumed that 1 in 100 random mutations causes a genetic disease. Mutations at tryptophan (W) and cysteine (C) 
have the highest probability of causing a disease. This correlates with the fact that these are the most highly conserved amino acids in evolution [10].
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mutations may cause late-onset human diseases without
strong selection in evolution. Alternatively, a particular
amino-acid substitution can be damaging to a human protein
but be relatively frequent in the homologous family due to
compensatory mutations. Such substitutions may account for
deleterious mutations with low GR scores.
Estimation of the maximal rate of mutations with 
impact on human health
From Figure 6 we can estimate the maximum rate of random
mutations with significant impact on human health (that is,
an impact similar to mutations currently annotated in MIM).
We note that the mutation rate we estimate (a fraction of
newly created deleterious mutations) is different from the
fraction of existing SNPs with deleterious effects on protein
function (estimated previously [1,2,23]). The comparison
between the distribution of random SNP mutations (cyan)
and disease mutations (red) suggests that about 10% of the
randomly generated mutations have GR scores greater than
6. Such a score corresponds to approximately 40% of the dis-
ease mutations. As a result, the total rate of the disease muta-
tions cannot be larger than one quarter of the random
mutation rate. Thus, one expects, at most, 25% of random
nonsynonymous mutations to be as damaging as mutations
currently annotated in MIM (similar estimates are obtained
using GR cutoffs larger than 6).
This estimate has a simple biochemical rationale, as muta-
genesis experiments on different proteins suggest that less
The relative mutation probabilities as a function of mutation site  conservation and solvent accessibility Figure 5
The relative mutation probabilities as a function of mutation site 
conservation and solvent accessibility. Relative mutation probability as a 
function of (a) evolutionary conservation of the mutation site (measured 
using relative entropy), and (b) solvent accessibility of the mutation site in 
the protein structure. Because the overall probability that a random 
mutation will cause a genetic disease or be observed as a polymorphism is 
not known, the probabilities have only relative meaning within each 
mutation class (disease, synonymous, nonsynonymous). To show different 
trends clearly, the relative probabilities were normalized to 1 within each 
class. Conservation of mutation sites in evolution was characterized by the 
relative entropy using close sequence homologs (see Materials and 
methods). The solvent accessibility of mutation sites was calculated using 
the program NACESS [41]. An increase in the degree of evolutionary 
conservation increases the probability of deleterious mutations and 
decreases the probability of nonsynonymous benign SNPs (a). An increase 
in the degree of solvent accessibility decreases the probability of 
deleterious mutations and increases the probability of nonsynonymous 
benign SNPs (b). Synonymous mutations do not change amino-acid 
sequences and are predominantly neutral. Consequently, the probability 
that a synonymous mutation will be deleterious is relatively constant 
across sites.
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Cumulative probability of the Grantham ratio (GR) for different classes of 
residues in proteins. Black, all (wild-type) protein residues; blue, original 
(wild-type) residues at the sites of benign SNPs; green, mutant residues at 
the sites of benign SNPs; cyan, residues generated by computer simulation 
of random mutations based on the amino-acid mutation frequencies; red, 
disease-causing residues from MIM. The Grantham ratio characterizes the 
degree of the residue's dissimilarity to the amino acids observed at the 
same position in evolutionary homologs (see Materials and methods). High 
GR values indicate radical mutations, whereas GR values that are small or 
around 1 indicate conservative mutations. The GR distributions 
demonstrate how purifying selection affects the observed mutation 
spectra. Comparison of the GR scores for original residues (black and 
blue) and disease-causing residues shows that more than half of disease 
mutations are radical (GR > 2) and are almost never observed in 
evolution.
Conservative mutations Radical mutations
All protein residues
Wild-type residues at benign SNP sites
Mutant residues at benign SNP sites
Randomly generated mutations
Disease mutations
C
u
m
u
l
a
t
i
v
e
 
p
r
o
b
a
b
i
l
i
t
i
e
s
 
(
%
)
Grantham ratio score
0
02468 1 0
10
20
30
40
50
60
70
80
90
100R72.8 Genome Biology 2003,     Volume 4, Issue 11, Article R72       Vitkup et al. http://genomebiology.com/2003/4/11/R72
Genome Biology 2003, 4:R72
than 30% of random mutations substantially damage biolog-
ical function or stability of proteins [26-29].
Using the recent estimate of the human mutation rate of 175
mutations per diploid genome per generation [30] (corre-
sponding to approximately two to three nonsynonymous
mutations), we conclude that the rate of nonsynonymous
mutations with serious impact on human health should be
less than one per diploid genome per generation. This is prob-
ably a substantial overestimation of the rate because we
assume that all human genes are as important for human
health as the well-annotated disease genes currently in the
MIM database. We emphasize that the rate of health-damag-
ing nonsynonymous mutations is smaller than the total rate
of deleterious human mutations, which is estimated to be
larger than one [30,31].
The present analysis, together with other recent studies [1-
4,23], establishes the basis for understanding the spectrum of
deleterious human mutations. The amino-acid substitution
matrices, such as PAM [10] and BLOSUM [32], apart from
playing a fundamental role in sequence alignment, qualita-
tively characterize the evolutionary interchangeability of
amino acids averaged over many protein families. The disease
spectrum, characterized by our analysis, explores another
important aspect of evolution, namely the generation of dele-
terious mutations. Because of all mammalian species have a
broadly similarity physiology, the properties of the disease
spectrum should be general, at least for mutations leading to
early-onset diseases. We anticipate that understanding the
disease spectrum will allow one to predict, in advance, the
rates and potential medical consequences of all possible sin-
gle-nucleotide mutations in the human genome.
Materials and methods
Calculation of mutation spectra
The spectrum of expected amino-acid mutation frequencies
(Figure 1a) was generated using the matrix of neighbor-
dependent nucleotide mutation rates obtained by Hess et al.
[13] (Additional data file 1). The neighbor-dependent
mutation matrix was calculated by Hess et al. on the basis of
20,200 substitutions in aligned gene/pseudogene human
sequences; the relative mutation rates were calculated for the
four nucleotides in all 16 possible 5' and 3' neighborhoods. To
obtain the expected amino-acid mutation frequencies for a
given collection of genes, we simulated all possible single-
nucleotide mutations with appropriate rates, and recorded
the corresponding amino-acid changes. The nucleotide muta-
tional spectrum of individual genes may be affected by the
presence of so-called mutation hot spots [33-35]. However,
on average, there is only a small influence of the surrounding
DNA sequence (beyond nearest 5' and 3' neighbors) on the
relative nucleotide mutation rates [17].
The interspecies spectrum of amino-acid mutation frequen-
cies (Figure 1d) was calculated on the basis of Dayhoff's PAM1
matrix. The original PAM1 matrix [10] gives the probabilities
of amino-acid substitutions over small evolutionary dis-
tances. These probabilities were multiplied by the amino-acid
frequencies in human genes for direct comparison with the
expected, disease, and benign SNPs matrices.
Structural and evolutionary analysis of mutations
The list of disease genes obtained from SWISS-PROT was fil-
tered using the program PSEG [36] to exclude genes with a
significant fraction of low-complexity regions. As a result of
the filtering, six genes for collagen proteins were excluded
from the original set of 436 genes. Mutations at Gly residues
constitute more than 50% of the collagen disease mutations
(due to the collagen structural motif). Because of this bias, the
collagen mutations were excluded from all calculations. If the
collagen mutations are included, the total fraction of disease
mutations at Gly (Figure 4a) increases from 12% to 15%.
Membrane proteins and transmembrane protein regions
were detected using the program TMHMM [14] with standard
parameters. Out of 430 disease genes, 105 (24%) were classi-
fied as membrane proteins on the basis of the presence of at
least two distinct transmembrane domains. To characterize
the evolutionary conservation of mutation sites we used
BLASTGP to search the nrdb90 database [37] for homologs
with greater than 30% sequence identity. The nrdb90 data-
base constitutes a nonredundant merge of sequence and
structural databases, which is filtered so that no pair of
sequences has greater than 90% sequence identity. The
homologs to each human protein were subsequently aligned
using the program CLUSTALW [38] with default parameters.
Only mutation sites covered by more than 10 homologous
sequences (excluding gaps) were used in the evolutionary
analysis. The multiple sequence alignments obtained using
CLUSTALW were used to characterize the relative entropy
(Kullback-Leibler distance) of the benign and disease muta-
tion sites. The relative entropy was calculated according to
the formula:
where the summation is over all amino-acid types n in the
alignment; P(n) is the probability of the amino acid n in the
column corresponding to mutation; Q(n) is the probability of
the amino acid n in all columns of the multiple sequence
alignment.
The multiple sequence alignments were also used to calculate
the Grantham ratio (GR) score according to the formula:
Re ative Entropy P n
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where D(A,B) is the Grantham measure of chemical dissimi-
larities between amino-acid residues A and B, Human_RES
is the human residues at the mutation site, RES(i)  is the
amino acid from the ith aligned sequence homolog at the
mutation site, and n  is the number of aligned sequences.
Qualitatively, the GR score is a measure of dissimilarity
between a human amino acid and the residues seen at the
same site in homologs. In total, the relative entropy and
Grantham ratio were calculated for 258 benign SNPs and
2,636 disease mutations.
To characterize the structural location of disease mutations
and benign SNPs, BLASTGP [39] was used to search the Pro-
tein Data Bank (PDB) [40] for sequences homologous to
known structures. Only sequences with greater than 30%
identity to human sequences over the entire length of the
alignment were considered. In total, the solvent accessibili-
ties were calculated for 110 benign SNPs and 840 disease
mutations. The solvent accessibility of mutation sites was
determined by the program NACCESS [41] using the water-
sphere radius of 1.4 Å. The solvent accessibility represents the
relative exposure of a residue X in a protein structure com-
pared to its exposure in the tripeptide Ala-X-Ala.
Calculation of relative mutation probabilities
The relative mutation probabilities shown in Figures 4b, 5a,
and 5b represent conditional probabilities. Specifically, the
conditional probability P(disease|descriptor), that a muta-
tion will cause a genetic disease given a certain property
(descriptor) of the mutation site was calculated according to
the formula:
where 'descriptor' represents solvent accessibility or evolu-
tionary conservation of the mutation site, P(descriptor|dis-
ease) is the probability that a disease mutation has a given
descriptor value, P(descriptor) is the probability that a ran-
dom mutation (disease or non-disease) has a given descriptor
value, and P(disease) is the probability that a random muta-
tion will cause a genetic disease. Importantly, because P(dis-
ease) is unknown, we can only estimate P(disease|descriptor)
up to a constant (assuming certain P(disease) value). Conse-
quently, we refer to P(disease|descriptor) as relative muta-
tion probabilities. The probability that a random mutation
has a given descriptor value P(descriptor) was estimated by
simulating random single-nucleotide mutations using the
expected amino-acid mutation frequencies (Figure 1a).
Additional data files
The following additional data are included with the online
version of this article: a list of relative mutation rates (Addi-
tional data file 1), a list of disease mutations (Additional data
file 2), a list of disease mutation genes (Additional data file 3),
a list of SNPs used in the analysis (Additional data file 4), and
the Grantham ratio scores (Additional data file 5).
Additional data file 1 A list of relative mutation rates A list of relative mutation rates Click here for additional data file Additional data file 2 A list of disease mutations A list of disease mutations Click here for additional data file Additional data file 3 A list of disease mutation genes A list of disease mutation genes Click here for additional data file Additional data file 4 A list of SNPs used in the analysis A list of SNPs used in the analysis Click here for additional data file Additional data file 5 The Grantham ratio scores The Grantham ratio scores Click here for additional data file
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